Slingshot Insights

Catalyst

Slingshot members are tracking this event:

Gilead (GILD) Plans to Submit FDA Application for Sofosbuvir/Velpatasvir/Voxilaprevir in Treatment-Experienced Genotype 1-6 Chronic HCV-Infected Patients by End of 2016

Source Link:: http://www.gilead.com/news/press-releases/2016/10/gilead-announces-svr12-rates-from-four-phase-3-studies-of-a-oncedaily-fixeddose-combination-of-sofosbuvir-velpatasvir-and-voxilaprevir-in-treatmentna%C3%AFve-and-treatmentexperienced-genotype-16-chronic-hcvinfected-patients

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies

Importance

High

Medium

Low

Impact on Stocks

GILD

100%

SIGN ME UP
I want to vote! LOG ME IN
Now!

Slingshot Insights Explained

JOIN FOR FREE TODAY

Catalyst Date

Occurred on:

Dec 08, 2016

Occurred Source:

http://www.gilead.com/news/press-releases/2016/12/gilead-submits-new-drug-application-to-us-food-and-drug-administration-for-the-investigational-single-tablet-regimen-sofosbuvirvelpatasvirvoxilaprevir

Related Projects

Don’t see a project related to the catalyst you care about?

Related Keywords Fda, Regulatory Application, Sofosbuvir, Velpatasvir, Voxilaprevir, Triple Combo Pill, Treatment-experienced, Genotype 1-6, Chronic Hcv